Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Inclusion Criteria: * Have biopsy-confirmed non-Hodgkin lymphoma, of any type * Must be eligible for autologous transplantation according to institutional guidelines * Eastern Cooperative Oncology Group performance status of 0 or 1 * Karnofsky performance status of 70 to 100 * Negative for human immunodeficiency virus (HIV) * prior to the start of mobilization, subjects must have: * Absolute neutrophil count of \>= 1.2 x 10\^9/L * Platelet count of \>= 100 x 10\^9/L * Creatinine clearance \>= 30 mL/minute * All patients must be able to comprehend and sign informed consent * If childbearing potential must either agree to complete abstinence from heterosexual intercourse or effective means of contraception during stem cell mobilization and for at least 3 months following last plerixafor dose; female patients will undergo pregnancy test prior to stem cell mobilization therapy Exclusion Criteria: * Have had previous transplants and/or prior mobilization attempts * Have evidence of progressive non-Hodgkin lymphoma * Have evidence of bone marrow involvement of lymphoma at time of transplant staging * Had evidence of active central nervous system (CNS) involvement * Have had previous radiation of the pelvic area * Have had prior radioimmunotherapy * Have received experimental therapy within 2 weeks of enrollment * Be currently enrolled in another investigational protocol * Have prior history of other malignancies, excluding basal cell carcinoma or squamous cell carcinoma o…